Long-lasting fragrance sets and their applications

Abstract

This invention provides a long-lasting fragrance kit comprising: (i) dosage form A, which comprises: 10-20 wt% oil, 0.01-40 wt% fragrance raw material, 3-25 wt% hydrogenated polydimethylsiloxane, 5-35 wt% vinyl polydimethylsiloxane, 1-10 wt% emulsifier, optionally 1-10 wt% silica, and a carrier acceptable in the cosmetic field; and (ii) dosage form B, which comprises: 1-10 wt% colloidal platinum composition, 1-10 wt% light-scattering particles, and a carrier acceptable in the cosmetic field; wherein the colloidal platinum composition comprises: 0.1-10 wt% platinum salt, 1-20 wt% fatty acid with 8-30 carbon atoms, 0.01-5 wt% organosilane with 10-60 carbon atoms, and a solvent acceptable in the cosmetic field, wherein the solvent is propylene glycol. This invention also relates to the application of the kit in the cosmetic field.

Description

Technical Field

[0001] This invention relates to perfume products in the field of cosmetics, specifically to a long-lasting fragrance set and its application. Background Technology

[0002] Studies have shown that aromatic substances can improve people's psychological and physiological states. Products with suitable aromas undoubtedly enhance their appeal and competitiveness. Therefore, fragrances, perfumes, and essential oils play a crucial role in industries such as daily chemicals, furniture, construction, and clothing. In the daily chemical sector, aromatic products account for a large proportion, with sales figures increasing year by year. Personal aromatic products mainly consist of perfumes and solid perfumes. Perfumes can be mainly divided into three different forms: alcoholic liquids, emulsions, and pastes. Generally speaking, they are formulated with fragrances, perfumes, or essential oils and solvents. Solid perfumes are mainly formulated with fragrances, perfumes, or essential oils plus solid solvents or thickened liquid solvents. Fragrances, perfumes, and essential oils are inherently volatile. Their rapid evaporation during use results in a short-lasting fragrance. Therefore, the length of time a fragrance lasts is a key indicator in evaluating a fragrance product. How to improve the lasting fragrance of perfumes or solid perfumes has become a research focus for industry researchers.

[0003] Currently, there are two main technical approaches to improving the longevity of fragrances, flavorings, and essential oils:

[0004] First: Encapsulation technology. This involves encapsulating fragrances, flavorings, or essential oils using materials such as liposomes, dextrin, modified starch, polyvinyl alcohol, silica, polyacrylates, polyurethane, gelatin, or chitosan through physical-mechanical methods, chemical synthesis, or physicochemical methods, controlling the size to the nanometer or micrometer scale. These encapsulated substances are then added to the desired formulation. Microencapsulated fragrances are convenient to add to different applications and formulations, making the process relatively easy. This is the mainstream technology adopted by major fragrance companies. However, the complex pre-encapsulation process inevitably leads to a relatively high price. Furthermore, while it controls the slow release of fragrance and enhances the lasting power, it doesn't solve the problem of how to better lock the microcapsules onto the skin, so the longevity of the fragrance is still somewhat lacking.

[0005] Second: Adsorption technology, which uses nanofiber materials such as cellulose to adsorb fragrances before adding them to the formula. However, such adsorption materials are difficult to apply in balm products. On the one hand, it increases additional costs, and on the other hand, the amount of cellulose and other materials that can be added to balms is also limited.

[0006] Therefore, there is a need in this field to develop a new technology that can achieve long-lasting fragrance retention of perfumes, flavorings, or essential oils in balm products without requiring cumbersome encapsulation techniques or the addition of additional adsorbent materials, thereby helping manufacturers to develop balm products more simply, economically, and conveniently. Summary of the Invention

[0007] On one hand, the present invention provides a long-lasting fragrance set, which includes:

[0008] (i) Dosage form A, wherein dosage form A comprises:

[0009] 10-20% by weight of oil,

[0010] 0.01-40% by weight of fragrance raw materials,

[0011] 3-25% by weight of hydrogenated polydimethylsiloxane, with a viscosity of 10 to 130 cSt at 25°C.

[0012] 5-35% by weight of vinyl polydimethylsiloxane, with a viscosity of 55,000 to 95,000 cSt at 25°C.

[0013] 1-10% by weight of emulsifier,

[0014] Optionally, 1-10% by weight of silica, and

[0015] Acceptable carriers in the cosmetics field; and

[0016] (ii) Dosage form B, wherein dosage form B comprises:

[0017] 1-10% by weight of colloidal platinum composition,

[0018] 1-10% by weight of light-scattering particles,

[0019] Acceptable carriers in the cosmetics industry;

[0020] The colloidal platinum composition comprises:

[0021] 0.1-10% by weight of platinum salts,

[0022] 1-20% by weight of fatty acids with 8-30 carbon atoms

[0023] 0.01-5% by weight of organosilanes with 10-60 carbon atoms,

[0024] A solvent acceptable in the cosmetics industry, wherein the solvent is propylene glycol.

[0025] In a preferred embodiment, the emulsifier in dosage form A is a polydimethylsiloxane PEG-10 / 15 crosslinked polymer.

[0026] In a preferred embodiment, the silica in dosage form A is selected from: silica, silylated silica, dimethylsilylated silica, polydimethylsiloxane silylated silica, hydrated silica, or combinations thereof.

[0027] In a preferred embodiment, the colloidal platinum composition in dosage form B further comprises polyvinylpyrrolidone with a K value of 28-34.

[0028] In a preferred embodiment, the platinum salt in the colloidal platinum composition of dosage form B is selected from: chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate, or combinations thereof.

[0029] In a preferred embodiment, the fatty acids in the colloidal platinum composition of dosage form B are selected from: palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid, or combinations thereof.

[0030] In a preferred embodiment, the organosilane in the colloidal platinum composition of dosage form B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane, or a combination thereof.

[0031] In a preferred embodiment, the light-scattering particles in dosage form B are nylon-12 and triisostearic acid isopropoxytitanium salt.

[0032] In a preferred embodiment, dosage form B further comprises the following components: silicone oil, silicone elastomer, emulsifier, polyol, or a combination thereof.

[0033] In a preferred embodiment, the kit of the present invention is in the form of a two-dosage package or two separate packages.

[0034] On the other hand, the present invention provides the application of the kit in the field of cosmetics, wherein the cosmetics are used to achieve a long-lasting fragrance effect.

[0035] On the other hand, the present invention also relates to a method of using the kit, comprising applying dosage form A evenly to the skin surface until absorbed, and then applying dosage form B to the skin surface. Detailed Implementation

[0036] This invention provides a long-lasting fragrance kit, comprising formulation A and formulation B. Formulation A is the first-step application product, containing fragrance ingredients (e.g., fragrance, perfume, essential oil, or a combination thereof), film-forming monomers vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, and silica. Formulation B is the second-step application product, containing colloidal platinum and light-scattering particles. After using the long-lasting fragrance kit prepared according to the method of this invention, a uniform, light, and fragrant coating was formed on the skin surface. Unexpectedly, the test results showed that a long-lasting fragrance of 24 hours or more could be achieved.

[0037] To provide a more concise description, some of the quantitative expressions given herein are not modified by the term "approximately". It should be understood that, whether or not the term "approximately" is explicitly used, each quantity given herein is intended to refer to an actual given value, and also to an approximation of such given values ​​that can be reasonably inferred by one of ordinary skill in the art, including approximations of such given values ​​caused by experimental and / or measurement conditions.

[0038] To provide a more concise description, some quantities in this document are described as a range from approximately X to approximately Y. It should be understood that when describing a range, the range is not limited to the upper and lower limits stated, but should include the entire range from approximately X to approximately Y, or any quantities in between.

[0039] I.Dosage Form A

[0040] Formulation A in the long-lasting fragrance kit described in this application is a first-step application product containing fragrance ingredients (e.g., fragrance, perfume, essential oil or a combination thereof), vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, emulsifier, and optional silica.

[0041] Fragrance raw materials

[0042] The fragrance ingredients included in dosage form A of the kit of this invention are a general term, including fragrances, flavorings, essential oils, or combinations thereof. For example, this invention can use various commercially available rose water, rose extract, rose oil, gardenia extract, gardenia oil, mixed lavender oil, lavender water, lavender flower extract, sandalwood oil, sandalwood extract, jasmine water, jasmine oil, jasmine flower extract, Rosa damascena water, Rosa damascena oil, Rosa damascena flower extract, tulip flower extract, etc.

[0043] In some embodiments of the present invention, the content of fragrance raw material in dosage form A of the kit described in this application is 0.01-40% by weight. In some embodiments of the present invention, dosage form A of the kit contains 0.1%-40% by weight of fragrance raw material. In some embodiments of the present invention, dosage form A of the kit contains 0.1%-30% by weight of fragrance raw material. In some embodiments of the present invention, dosage form A of the kit contains 0.1%-20% by weight of fragrance raw material. In some embodiments of the present invention, dosage form A of the kit contains 0.1%-10% by weight of fragrance raw material.

[0044] siloxane

[0045] The formulation A of the kit of this invention contains vinyl dimethicone, with the INCI name VINYLDIMETHICONE. The vinyl dimethicone used in this invention is required to have a viscosity of 55,000 to 95,000 cSt at 25°C. In a preferred embodiment, the vinyl dimethicone used in this invention has a viscosity of 55,000 to 80,000 cSt. In another preferred embodiment, the vinyl dimethicone used in this invention has a viscosity of 60,000 to 80,000 cSt.

[0046] In some embodiments of the present invention, the content of vinyl polydimethylsiloxane in dosage form A of the kit described in this application is 5-50% by weight. In some embodiments of the present invention, dosage form A of the kit contains 5-35% by weight of vinyl polydimethylsiloxane. In some embodiments of the present invention, dosage form A of the kit contains 5-20% by weight of vinyl polydimethylsiloxane.

[0047] The dosage form A of the kit of this invention contains hydrogenated polydimethylsiloxane, with the INCI name HYDROGENDIMETHICONE. The viscosity of the hydrogenated polydimethylsiloxane used in this invention is required to be 10 to 130 cSt at 25°C. In a preferred embodiment, the viscosity of the hydrogenated polydimethylsiloxane used in this invention is 15 to 100 cSt.

[0048] In some embodiments of the present invention, the content of hydrogenated polydimethylsiloxane in dosage form A of the kit described in this application is 1-35% by weight. In some embodiments of the present invention, dosage form A of the kit contains 3-25% by weight of hydrogenated polydimethylsiloxane. In some embodiments of the present invention, dosage form A of the kit contains 5-20% by weight of hydrogenated polydimethylsiloxane.

[0049] Siloxanes (e.g., hydrogenated polydimethylsiloxane and / or vinyl polydimethylsiloxane in dosage form A) can crosslink on the skin in situ (e.g., through the action of colloidal platinum in dosage form B) to form a transparent, invisible film with properties such as fragrance locking and sustained-release odor.

[0050] emulsifier

[0051] The dosage form A of the kit of the present invention contains an emulsifier. In one specific embodiment, the emulsifier used in dosage form A is a polydimethylsiloxane PEG-10 / 15 crosspolymer.

[0052] In some embodiments of the present invention, the content of polydimethylsiloxane PEG-10 / 15 crosslinked polymer in dosage form A of the kit described in this application is 1-10% by weight. In some embodiments of the present invention, dosage form A of the kit contains 1-5% by weight of polydimethylsiloxane PEG-10 / 15 crosslinked polymer. In some embodiments of the present invention, dosage form A of the kit contains 2-5% by weight of polydimethylsiloxane PEG-10 / 15 crosslinked polymer.

[0053] silica

[0054] The dosage form A of the kit of the present invention optionally includes silica. The silica used in dosage form A is a general term that includes silica, silylated silica, dimethylsilylated silica, polydimethylsiloxane silylated silica, hydrated silica, and other combinations thereof.

[0055] In some embodiments of the present invention, the silica content in dosage form A of the kit described in this application is 1-10% by weight. In some embodiments of the present invention, dosage form A of the kit contains 5-10% by weight of silica.

[0056] Other ingredients in dosage form A

[0057] The dosage form A of the kit of the present invention may also contain other ingredients. For example, dosage form A of the kit of this application may contain oils, thickeners, preservatives, pH adjusters, etc.

[0058] In some specific embodiments, the oil contained in dosage form A of the kit is selected from: isononyl isononanoate, polydimethylsiloxane, or combinations thereof. In some preferred embodiments, the amount of oil in dosage form A is 10-20% by weight.

[0059] In some specific embodiments, dosage form A of the kit comprises an acrylate / C10-30 alkanol acrylate crosspolymer. In some preferred embodiments, the amount of the acrylate / C10-30 alkanol acrylate crosspolymer in dosage form A is 0.1-5% by weight. In some preferred embodiments, the amount of the acrylate / C10-30 alkanol acrylate crosspolymer in dosage form A is 0.5-1.5% by weight.

[0060] In some specific embodiments, dosage form A of the kit contains phenoxyethanol. In some preferred embodiments, the amount of phenoxyethanol in dosage form A is 0.1-1% by weight.

[0061] In some specific embodiments, dosage form A of the kit contains tromethamine. In some preferred embodiments, the amount of tromethamine in dosage form A is 0.1-1% by weight.

[0062] Preparation method of dosage form A

[0063] The present invention also provides a method for preparing dosage form A.

[0064] Dosage form A of the present invention can be prepared according to the following weight percentages of raw materials: 10-20% oil, 0.01-40% fragrance raw material, 3-25% hydrogenated polydimethylsiloxane, 5-35% vinyl polydimethylsiloxane, 1-10% silica, 2-5% emulsifier, 0.5-1.5% thickener, 0.1-1% preservative, and 40-60% deionized water.

[0065] Specifically, the preparation method of dosage form A of the present invention includes the following steps:

[0066] (a) Mix the fragrance raw materials, vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oil and emulsifier evenly to form the oil phase;

[0067] (b) Take a portion of deionized water, add a thickener, dissolve and swell it completely, add preservatives and other ingredients to form the aqueous phase;

[0068] (c) The aqueous phase is slowly added to the oil phase to obtain formulation A.

[0069] In one specific embodiment, the preparation process of dosage form A includes the following steps: At a temperature range of 25-60°C, fragrance raw materials (fragrance, flavoring, or essential oil), vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oils, and emulsifier are mixed evenly to form the oil phase. A portion of deionized water is taken, and a thickener is added, dissolved, and swollen to form the aqueous phase. The remaining deionized water and preservative are mixed evenly and added to the aqueous phase. At a temperature range of 25-60°C, the aqueous phase is slowly added to the oil phase, stirred and homogenized for 5-15 minutes; stirring is continued, and the mixture is slowly cooled to room temperature to form a milky white cream, which is then sealed and stored away from light.

[0070] II. Dosage Form B

[0071] Formulation B in the long-lasting fragrance kit described in this application is a second-step application product containing a colloidal platinum composition and light-scattering particles.

[0072] Colloidal platinum composition

[0073] This application is the first to discover that the selection of solvents and additives is crucial in the preparation of colloidal platinum compositions. The invention innovatively discovers that by using specific solvents (e.g., propylene glycol) and additives (e.g., fatty acids and organosilanes), the resulting colloidal platinum compositions exhibit particle sizes in the range of 0.5-5 nm, and the compositions maintain long-term stability.

[0074] In some embodiments of the present invention, the content of the colloidal platinum composition in dosage form B of the kit described in this application is 0.01-10% by weight. In some embodiments of the present invention, dosage form B of the kit contains 0.01-5% by weight of the colloidal platinum composition. In some embodiments of the present invention, dosage form B of the kit contains 1-5% by weight of the colloidal platinum composition.

[0075] Metallic platinum salts of colloidal platinum compositions

[0076] This invention provides a colloidal platinum composition comprising colloidal platinum, a raw material used in top-tier cosmetics, as an active ingredient.

[0077] In embodiments of the present invention, the platinum salt is selected from: chloroplatinic acid (CAS: 16941-12-1, chemical formula: H2PtCl6·6H2O), potassium hexachloroplatinate (CAS: 16921-30-5, chemical formula: K2PtCl6), sodium chloroplatinate (CAS: 19583-77-8, chemical formula: Na2PtCl6·6H2O), and platinum acetylacetonate (CAS: 15170-57-7, chemical formula: C...). 10 H 14 One or a combination thereof (O4Pt). In a preferred embodiment, the platinum salt is chloroplatinic acid.

[0078] In some embodiments of the present invention, the content of platinum salt in the colloidal platinum composition is 0.1-10% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 0.1-8% by weight of platinum salt. In some embodiments of the present invention, the composition contains 0.1-5% by weight of platinum salt. In some embodiments of the present invention, the composition contains 0.1-4% by weight of platinum salt.

[0079] Solvents for colloidal platinum compositions

[0080] Colloidal platinum is a liquid in which negatively charged platinum nanoparticles are suspended. Ethylene glycol is commonly used as a solvent in the preparation of colloidal platinum compositions. For example, the use of ethylene glycol is reported in the literature (Nano Today, 2009, 4, 143-164). However, ethylene glycol has certain toxicity and can damage internal organs such as the kidneys, liver, stomach, and intestines. Furthermore, ethylene glycol is a restricted organic solvent listed in the Appendix II of the 2010 edition of the Chinese Pharmacopoeia.

[0081] Propylene glycol, whose INCI name is PROPYLENE GLYCOL, is used in this application. This application unexpectedly discovers that using propylene glycol as a solvent for preparing colloidal platinum compositions not only retains the advantages of propylene glycol, such as being non-toxic, non-corrosive, biodegradable, and having better safety, but also maintains the stability of the prepared colloidal platinum compositions. Therefore, this application is the first to discover that propylene glycol is the optimal solvent for preparing colloidal platinum compositions.

[0082] In some embodiments of the present invention, the amount of solvent in the colloidal platinum composition is equal to or greater than 50% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 40-95% by weight of solvent. In some embodiments of the present invention, the composition contains 50-90% by weight of solvent. In some embodiments of the present invention, the composition contains 60-90% by weight of solvent. In some embodiments of the present invention, the composition contains 70-90% by weight of solvent.

[0083] Additives for colloidal platinum compositions

[0084] The present invention unexpectedly discovered that fatty acids and organosilanes play a key role in the preparation of colloidal platinum compositions.

[0085] The addition of fatty acids plays a crucial role in controlling the particle size in colloidal platinum.

[0086] Fatty acids are a class of compounds composed of carbon, hydrogen, and oxygen, and are the main components of neutral fats, phospholipids, and glycolipids. Fatty acids can be further classified according to their carbon chain length: short-chain fatty acids, which have fewer than 6 carbon atoms in their carbon chain, also known as volatile fatty acids; medium-chain fatty acids, which have 6-12 carbon atoms in their carbon chain, mainly composed of caprylic acid (C8) and capric acid (C10); and long-chain fatty acids, which have more than 12 carbon atoms in their carbon chain. In a preferred embodiment of the present invention, the additive used is a medium-chain or long-chain fatty acid. In a preferred embodiment, fatty acids with 8-30 carbon atoms are used. In a more preferred embodiment, fatty acids with 10-26 carbon atoms are used. In an even more preferred embodiment, fatty acids with 12-22 carbon atoms are used. In specific embodiments, fatty acids with 12, 14, 16, 18, 20, or 22 carbon atoms are used.

[0087] Fatty acids can be classified into three categories based on the saturation or unsaturation of their hydrocarbon chains: saturated fatty acids, which have no unsaturated bonds on their hydrocarbon chains; monounsaturated fatty acids, which have one unsaturated bond on their hydrocarbon chains; and polyunsaturated fatty acids, which have two or more unsaturated bonds on their hydrocarbon chains. Saturated, monounsaturated, or polyunsaturated fatty acids can be used in the colloidal platinum compositions of this invention.

[0088] In a preferred embodiment, the fatty acid is selected from one or a combination of palmitic acid, oleic acid, stearic acid, lauric acid, and behenic acid. In the most preferred embodiment, the fatty acid is oleic acid.

[0089] In some embodiments of the present invention, the amount of fatty acids in the colloidal platinum composition is 1-20% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 1-15% by weight of fatty acids. In some embodiments of the present invention, the composition contains 2-15% by weight of fatty acids. In some embodiments of the present invention, the composition contains 3-10% by weight of fatty acids. In some embodiments of the present invention, the composition contains 5-10% by weight of fatty acids.

[0090] The addition of organosilanes helps maintain the long-term stability of colloidal platinum activity.

[0091] In some embodiments of the present invention, organosilanes with 10-60 carbon atoms are used. In a preferred embodiment, organosilanes with 10-30 carbon atoms are used. In a more preferred embodiment, organosilanes with 10-26 carbon atoms are used. In an even more preferred embodiment, organosilanes with 10-20 carbon atoms are used. In specific embodiments, organosilanes with 11, 14, 17, or 20 carbon atoms are used.

[0092] In a preferred embodiment, the organosilane is selected from one of trimethoxyoctylsilane, triethoxyoctylsilane, or a combination thereof. In a more preferred embodiment, the organosilane is trimethoxyoctylsilane.

[0093] In some embodiments of the present invention, the amount of organosilane in the colloidal platinum composition is 0.01-5% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 0.01-1% by weight of organosilane. In some embodiments of the present invention, the colloidal platinum composition contains 0.1-2% by weight of organosilane. In some embodiments of the present invention, the composition contains 0.1-1% by weight of organosilane. In some embodiments of the present invention, the composition contains 0.1-0.5% by weight of organosilane.

[0094] Other components in colloidal platinum composition

[0095] The colloidal platinum composition of the present invention may also contain other components.

[0096] For example, in one embodiment of the present invention, the composition further comprises polyvinylpyrrolidone (PVP). PVP is a nonionic polymer. PVP is classified into four levels according to its average molecular weight, conventionally represented by the K value. Different K values ​​represent corresponding ranges of average molecular weight of PVP. The K value is actually a characteristic value related to the relative viscosity of PVP aqueous solution, and viscosity is a physical quantity related to the molecular weight of polymers. Therefore, the K value can be used to characterize the average molecular weight of PVP. Generally, the larger the K value, the greater the viscosity and the stronger the adhesion.

[0097] In one specific embodiment, the K value of the polyvinylpyrrolidone contained in the composition is required to be in the range of 28 to 34.

[0098] In some embodiments of the present invention, the amount of polyvinylpyrrolidone in the colloidal platinum composition of this application is 1-30% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 2-30% by weight of polyvinylpyrrolidone. In some embodiments of the present invention, the composition contains 2-20% by weight of polyvinylpyrrolidone. In some embodiments of the present invention, the composition contains 2-15% by weight of polyvinylpyrrolidone. In some embodiments of the present invention, the composition contains 1-10% by weight of polyvinylpyrrolidone.

[0099] Preparation method of colloidal platinum composition

[0100] The present invention also provides a method for preparing the above-mentioned colloidal platinum composition.

[0101] The colloidal platinum composition of the present invention can be prepared according to the following weight percentages of raw materials: 0.1%-4% platinum salt, 2%-30% polyvinylpyrrolidone, 60%-90% propylene glycol, 5%-15% fatty acid, and 0.01%-1% organosilane.

[0102] Specifically, the method for preparing the colloidal platinum composition of the present invention includes the following steps:

[0103] (a) A first mixture is obtained by mixing a platinum salt, polyvinylpyrrolidone, and propylene glycol.

[0104] (b) Add fatty acids to the first mixture to obtain the second mixture;

[0105] (c) Add organosilane to the second mixture to finally obtain the colloidal platinum composition of the present invention.

[0106] In one specific embodiment, the preparation method of the colloidal platinum composition of the present invention includes the following steps: At room temperature, the platinum salt, polyvinylpyrrolidone, and propylene glycol are mixed uniformly according to the above-mentioned amounts. The mixture is rapidly stirred and heated to 110-200°C, and held at this temperature for 2-8 hours. Fatty acids are added, and the temperature is raised to 120-250°C, with stirring continuing for 30-90 minutes. The temperature is then lowered to 60-80°C, and an organosilane is added, maintaining this temperature while stirring for 30-90 minutes. Finally, the temperature is lowered to room temperature. The colloidal platinum is then discharged, and the preparation is complete. It is stored in a cool, dark place.

[0107] The colloidal platinum composition prepared by this invention has an average particle size of 0.5-5 nm. In a preferred embodiment, the colloidal platinum composition of this invention has an average particle size of 1-5 nm. In a further preferred embodiment, the colloidal platinum composition of this invention has an average particle size of 1-3 nm.

[0108] In the colloidal platinum composition prepared by this invention, more than 75% of the particles have a particle size in the range of 1.75 ± 0.5 nm. In a preferred embodiment, more than 80% of the particles in the composition have a particle size in the range of 1.75 ± 0.5 nm. In a more preferred embodiment, more than 90% of the particles in the composition have a particle size in the range of 1.75 ± 0.5 nm.

[0109] Light scattering particles

[0110] Formulation B in the long-lasting fragrance kit described in this application contains light-scattering particles. In some embodiments of the invention, the light-scattering particles include one or a combination of nylon-12 and isopropoxytitanium triisostearate, and silicone resin.

[0111] In some embodiments of the present invention, the content of light-scattering particles in dosage form B of the kit described in this application is 1-10% by weight. In some embodiments of the present invention, dosage form A of the kit contains 2-8% by weight of light-scattering particles. In some embodiments of the present invention, dosage form A of the kit contains 2-5% by weight of light-scattering particles.

[0112] Other ingredients in dosage form B

[0113] The dosage form B of the kit of the present invention may also contain other ingredients. For example, the dosage form A of the kit of this application may contain silicone oil, silicone elastomer, emulsifier, polyol, preservative, etc.

[0114] In some embodiments of the invention, dosage form B of the package contains cyclopentamericadimethylsiloxane. In some specific embodiments, dosage form B contains 10-20% by weight of cyclopentamericadimethylsiloxane.

[0115] In some embodiments of the invention, dosage form B of the package comprises a polydimethylsiloxane crosslinked polymer. In some specific embodiments, dosage form B comprises 1-15% by weight of the polydimethylsiloxane crosslinked polymer.

[0116] In some embodiments of the present invention, the polyol contained in dosage form B of the kit is selected from glycerol, butylene glycol, hexanediol, or combinations thereof. In some specific embodiments, dosage form B contains 20-40% by weight of the polyol.

[0117] In some embodiments of the invention, the emulsifier contained in dosage form B of the kit is selected from: cetyl PEG / PPG-10 / 1 polydimethylsiloxane, polydimethylsiloxane PEG-10 / 15 crosspolymer, or combinations thereof. In some specific embodiments, dosage form B contains 2-5% by weight of emulsifier.

[0118] Preparation method of dosage form B

[0119] The present invention also provides a method for preparing dosage form B.

[0120] Formulation B of the present invention can be prepared according to the following weight percentages of raw materials: silicone oil 10-20%, silicone elastomer 1-15%, emulsifier 2-5%, light scattering particles 2-8%, colloidal platinum composition 0.01-2%, polyol 20-40%, preservative 0.1-1%, and deionized water 25-45%.

[0121] Specifically, the preparation method of dosage form B of the present invention includes the following steps:

[0122] (a) The silicone oil, silicone elastomer, emulsifier, and light scattering particles are mixed evenly to form the oil phase;

[0123] (b) Take a portion of deionized water, add polyol and preservative, dissolve thoroughly, and use as the aqueous phase;

[0124] (c) Prepare colloidal platinum compositions as additive phases;

[0125] (d) The aqueous phase is slowly added into the oil phase, and then the additive phase is added to obtain formulation B.

[0126] In one specific embodiment, the preparation process of dosage form B includes the following steps: Silicone oil, silicone elastomer, emulsifier, and light-scattering particles are mixed uniformly within a temperature range of 25-60°C to form the oil phase. A portion of deionized water is taken, and polyol and preservative are added and dissolved thoroughly to form the aqueous phase. Colloidal platinum is added separately as the additive phase. Within a temperature range of 25-60°C, the aqueous phase is slowly added to the oil phase, and the mixture is stirred and homogenized for 5-15 minutes; then the additive phase is added, and the mixture is stirred and homogenized for another 5-15 minutes; an opaque gel is formed, and the gel is sealed and stored away from light.

[0127] III. Application of the Set

[0128] This invention also relates to the application of sets in the cosmetics field. Specifically, the long-lasting fragrance set described in this invention is suitable for the fragrance industry.

[0129] The application method of the long-lasting fragrance kit described in this invention is as follows: First, apply product A to the desired area of ​​the skin. After complete absorption, apply product B to the desired area and wait for 3 to 10 minutes. Using the kit of this invention achieves long-lasting fragrance, for example, the fragrance lasts for 4 hours or more, 8 hours or more, 12 hours or more, or 24 hours or more.

[0130] This invention enables a significant slow-release of fragrance, providing a long-lasting and captivating scent that lasts all day. The product forms a transparent, invisible film on the skin, allowing the alluring fragrance to be released slowly and persistently, extending its duration. It is unaffected by water or sweat.

[0131] The present invention will be further illustrated below with reference to specific embodiments. It is important to note that these embodiments are for illustrative purposes only and should not be construed as limiting the scope of protection of the invention. Those skilled in the art can make non-essential improvements and adjustments based on the above description of the invention. Test methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.

[0132] Example 1: Preparation of colloidal platinum composition

[0133] At room temperature, 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 85.5% propylene glycol are mixed thoroughly. The mixture is rapidly stirred and heated to 110°C, held at this temperature for 2 hours. 8% oleic acid is added, the temperature is raised to 120°C, and stirring continues for 30 minutes. The mixture is then cooled to 60°C, and 0.5% trimethoxyoctylsilane is added, maintaining this temperature while stirring for 30 minutes. Finally, the mixture is cooled to room temperature. The colloidal platinum is then discharged and stored in a cool, dark place.

[0134] Comparative Example 1: Preparation of Colloidal Platinum Compositions

[0135] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 86% propylene glycol thoroughly. Stir rapidly, heat to 110°C, and maintain this temperature for 2 hours. Add 8% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Finally, cool to room temperature. Discharge the mixture; the colloidal platinum is now ready. Store in a cool, dark place.

[0136] Comparative Example 2: Preparation of Colloidal Platinum Compositions

[0137] At room temperature, 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 93.5% propylene glycol were mixed thoroughly. The mixture was stirred rapidly and heated to 110°C, maintaining this temperature for 2 hours. The mixture was then cooled to 60°C, and 0.5% trimethoxyoctylsilane was added, while stirring at this temperature for 30 minutes. Finally, the mixture was cooled to room temperature. The colloidal platinum was then discharged and stored in a cool, dark place.

[0138] Comparative Example 3: Preparation of Colloidal Platinum Compositions

[0139] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 94% propylene glycol thoroughly. Stir rapidly and heat to 110°C, holding for 2 hours. Finally, cool to room temperature. Discharge the mixture; the colloidal platinum is now ready. Store in a cool, dark place.

[0140] Test Example 1: Stability Study of Colloidal Platinum Compositions

[0141] The stability evaluation method is as follows: The colloidal platinum compositions prepared in Example 1 and Comparative Examples 1-3 were placed in a high-temperature (40°C) stable constant temperature chamber and observed for 30 days. The presence of particulate solid precipitation, surface blackening, or layering was observed. If the sample remained normal and unchanged before and after a certain point within the 30-day period, it was considered "ok". The presence of particles indicated "precipitation", localized blackening indicated "blackening", and the appearance of two liquid layers indicated "layering". The results are shown in the table below.

[0142] Table 1: Stability Study of Different Additives

[0143]

[0144] As shown in Table 1, comparing the results of Example 1 and Comparative Example 1, it was found that if no organosilane was added as a stabilizer, the colloidal platinum composition would turn black after 30 days. Comparing the results of Example 1 and Comparative Example 2, it was found that if no fatty acid was added during the preparation of the colloidal platinum composition, solid precipitation and agglomeration would occur after 7 days. Comparing the results of Example 1 and Comparative Example 3, it is shown that the addition of fatty acids and organosilanes plays an important role in the stability of the colloidal platinum composition during the preparation process.

[0145] Example 2: Preparation of colloidal platinum composition

[0146] At room temperature, 0.5% potassium hexachloroplatinate, 3% polyvinylpyrrolidone, and 90.2% propylene glycol were mixed thoroughly. The mixture was stirred rapidly and heated to 110°C, maintaining this temperature for 2 hours. 6% stearic acid was added, and the temperature was raised to 120°C, with stirring continuing for 30 minutes. The mixture was then cooled to 60°C, and 0.3% triethoxyoctylsilane was added, maintaining this temperature while stirring for 30 minutes. Finally, the mixture was cooled to room temperature. The colloidal platinum was then discharged and stored in a cool, dark place.

[0147] Example 3: Preparation of colloidal platinum composition

[0148] At room temperature, 2.5% sodium chloroplatinate, 15% polyvinylpyrrolidone, and 67.5% propylene glycol were mixed thoroughly. The mixture was rapidly stirred and heated to 110°C, maintaining this temperature for 2 hours. 14% lauric acid was added, and the temperature was raised to 120°C, with stirring continuing for 30 minutes. The mixture was then cooled to 60°C, and 1% trimethoxyoctylsilane was added, maintaining this temperature while stirring for 30 minutes. Finally, the mixture was cooled to room temperature. The colloidal platinum was then discharged and stored in a cool, dark place.

[0149] Example 4: Preparation of colloidal platinum composition

[0150] At room temperature, 3% platinum acetylacetonate, 20% polyvinylpyrrolidone, and 66.1% propylene glycol were mixed thoroughly. The mixture was stirred rapidly and heated to 110°C, maintaining this temperature for 2 hours. 10% behenic acid was added, and the temperature was raised to 120°C, with stirring continuing for 30 minutes. The mixture was then cooled to 60°C, and 0.9% triethoxyoctylsilane was added, maintaining this temperature while stirring for 30 minutes. Finally, the mixture was cooled to room temperature. The colloidal platinum was then discharged and stored in a cool, dark place.

[0151] Example 5: Preparation of colloidal platinum composition

[0152] At room temperature, 0.5% chloroplatinic acid, 0.2% platinum acetylacetonate, 10% polyvinylpyrrolidone, and 76.5% propylene glycol were mixed thoroughly. The mixture was rapidly stirred and heated to 110°C, maintaining this temperature for 2 hours. Then, 2% palmitic acid and 10% oleic acid were added, and the temperature was raised to 120°C, with stirring continuing for 30 minutes. The mixture was then cooled to 60°C, and 0.8% trimethoxyoctylsilane was added, maintaining this temperature while stirring for 30 minutes. Finally, the mixture was cooled to room temperature. The colloidal platinum was then discharged and stored in a cool, dark place.

[0153] Example 6: Preparation of colloidal platinum composition

[0154] At room temperature, 0.1% sodium chloroplatinate, 0.1% platinum acetylacetonate, 3% polyvinylpyrrolidone, and 92.7% propylene glycol were mixed thoroughly. The mixture was rapidly stirred and heated to 110°C, maintaining this temperature for 2 hours. 1% stearic acid and 3% oleic acid were added, and the temperature was raised to 120°C, with stirring continuing for 30 minutes. The mixture was then cooled to 60°C, and 0.1% trimethoxyoctylsilane was added, maintaining this temperature while stirring for 30 minutes. Finally, the mixture was cooled to room temperature. The colloidal platinum was then discharged and stored in a cool, dark place.

[0155] Example 7: Preparation of colloidal platinum composition

[0156] At room temperature, mix 2% chloroplatinic acid, 2% sodium chloroplatinate, 30% polyvinylpyrrolidone, and 50% propylene glycol until homogeneous. Stir rapidly and heat to 110°C, maintaining this temperature for 2 hours. Add 15% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then cool to 60°C, add 1% trimethoxyoctylsilane, and maintain this temperature while stirring for 30 minutes. Finally, cool to room temperature. Discharge the mixture; the colloidal platinum is now ready. Store in a cool, dark place.

[0157] Test Example 2: Stability Study of Colloidal Platinum Compositions

[0158] The stability evaluation method is as follows: The colloidal platinum compositions prepared in Examples 2-7 were placed in a high-temperature (40℃) stable constant temperature chamber and observed for 30 days. The presence of particulate solid precipitation, surface blackening, or layering was observed. If the sample remained normal and unchanged before and after a certain time within the 30 days, it was considered "ok". The presence of particles indicated "precipitation", localized blackening indicated "blackening", and the appearance of two liquid layers indicated "layering". The results are shown in Table 2 below.

[0159] Table 2: Stability Study of Different Raw Materials

[0160]

[0161] As shown in Table 2, the results of Examples 2 to 5 show that the selected platinum salt in colloidal platinum can be chosen from one of chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, or platinum acetylacetonate, all of which yield good results. The results of Examples 4, 6, and 7 show that both trimethoxyoctylsilane and triethoxyoctylsilane can yield colloidal platinum compositions with good stability. By comparing all the above results, it is shown that in the process of preparing colloidal platinum, the selection of fatty acids such as palmitic acid, oleic acid, stearic acid, lauric acid, and behenic acid can all achieve satisfactory results.

[0162] The colloidal platinum compositions obtained in the above experiments not only exhibited good stability but also maintained a high level of activity. Since colloidal platinum can promote the cross-linking reaction of siloxanes, cosmetics containing siloxanes were first used as the first dosage form (dosage form A), and then cosmetics containing the colloidal platinum compositions were used as the second dosage form (dosage form B).

[0163] This study designed a dual-formula product: Formulation A containing siloxanes and Formulation B containing a colloidal platinum composition. Formulation A is pre-applied to a designated skin area and, after absorption, Formulation B is applied to the same area. The colloidal platinum composition promotes the cross-linking of siloxanes on the skin surface, achieving a long-lasting fragrance effect.

[0164] The following are examples of specific applications of the colloidal platinum compositions of the present invention in topical skin preparations, as well as the formulations and preparation methods of these dosage forms. "-" in the following tables indicates no additives. Information on the fragrance ingredients used in the following application and product examples is as follows:

[0165] Table 3

[0166]

[0167] Table 4: Formulation Composition Information for Dosage Form A (Product Examples 4 / 5 / 6 / 7, Application Example 1)

[0168]

[0169]

[0170] Table 5: Formulation Composition Information for Dosage Form B (Product Examples 4 / 5 / 6 / 7, Application Example 1)

[0171]

[0172] Product Example 4:

[0173] Preparation of dosage form A

[0174] Following the above formulation, within a temperature range of 25℃ to 60℃, thoroughly mix 18.00% of polydimethylsiloxane, 2.00% of isononyl isononanoate, 2% of rose extract, and 4% of polydimethylsiloxane PEG-10 / 15 crosspolymer to form the oil phase. Take 30% deionized water and add the acrylate / C10-30 alkanol acrylate crosspolymer, dissolving and swelling it completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase to the oil phase, stirring and homogenizing for 5–15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed, light-protected container.

[0175] Preparation of dosage form B

[0176] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 52.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0177] Product Example 5:

[0178] Preparation of dosage form A

[0179] Following the above formulation, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 10000 cSt), 10.00% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 8.00% polydimethylsiloxane, 2.00% isononyl isononanoate, 2.00% rose extract, and 4% polydimethylsiloxane PEG-10 / 15 crosspolymer to form the oil phase. Take 30% deionized water and add the acrylate / C10-30 alkanol acrylate crosspolymer, dissolving and swelling it completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0180] Preparation of dosage form B

[0181] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 52.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0182] Product Example 6:

[0183] Preparation of dosage form A

[0184] Following the above formulation, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 180000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% rose extract, and 4% polydimethylsiloxane PEG-10 / 15 crosspolymer to form the oil phase. Take 30% deionized water and add acrylate / C10-30 alkanol acrylate crosspolymer, dissolving and swelling completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase to the oil phase, stirring and homogenizing for 5–15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed, light-protected container.

[0185] Preparation of dosage form B

[0186] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 52.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0187] Product Example 7:

[0188] Preparation of dosage form A

[0189] Following the above formulation, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% rose extract, and 4% polydimethylsiloxane PEG-10 / 15 crosspolymer to form the oil phase. Take 30% deionized water and add acrylate / C10-30 alkanol acrylate crosspolymer, dissolving and swelling completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase to the oil phase, stirring and homogenizing for 5–15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed, light-protected container.

[0190] Preparation of dosage form B

[0191] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 52.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0192] Application Example 1:

[0193] Preparation of dosage form A

[0194] Following the above formulation, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 8% silica, 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% rose extract, and 4% polydimethylsiloxane PEG-10 / 15 crosspolymer to form the oil phase. Take 25% deionized water and add 0.5% acrylate / C10-30 alkanol acrylate crosspolymer, dissolving and swelling completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0195] Preparation of dosage form B

[0196] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 52.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0197] Test Example 3:

[0198] Test Method: Olfactory Identification: Thirty participants were selected, all of whom had undergone prior olfactory testing. They could easily distinguish between deionized water, 1% acetic acid, and 1% β-phenylethanol. The samples were placed in a temperature- and humidity-controlled room. Participants entered the room 30 minutes before each test. Product A was first applied to the desired area of ​​the skin and, after complete absorption, Product B was applied to the same area. The duration of the fragrance was then recorded at each time point. No fragrance was 0, weak fragrance was +, medium fragrance was ++, and strong fragrance was +++.

[0199] Table 6: Fragrance Longevity Test of Perfume Balm

[0200]

[0201] As shown in Table 6, compared to sample 1, samples 2-5 all exhibit excellent fragrance retention. Samples 2-3 achieve a fragrance retention of 8 hours, while samples 4-5 achieve a fragrance retention of 24 hours. The comparison between samples 2-4 indicates that the viscosity of vinyl polydimethylsiloxane has a certain impact on the final effect. Choosing relatively low viscosity (10000 cSt) or high viscosity (180000 cSt) is relatively unfavorable for the sustained release of fragrance raw materials (fragrances, flavorings, or essential oils). Choosing a moderate viscosity (60000 cSt) maintains good spreadability and film-forming properties, resulting in a longer sustained release and fragrance retention time. Comparing samples 4 and 5, the addition of silica has a slight impact on fragrance retention at 8 hours. The effect is not significant at other time points.

[0202] Application Example 2:

[0203] Preparation of dosage form A

[0204] According to the formulation dosage, within a temperature range of 25℃ to 60℃, thoroughly mix 35% vinyl polydimethylsiloxane (viscosity: 65000 cSt), 25% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% gardenia extract, 4% polydimethylsiloxane PEG-10 / 15 crosspolymer, and 10% silylated silica to form the oil phase. Take 3% deionized water and add 0.2% acrylate / C10-30 alkanol acrylate crosspolymer, dissolve and swell completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0205] Preparation of dosage form B

[0206] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinking polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinking polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 48.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 5% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0207] Application Example 3:

[0208] Preparation of dosage form A

[0209] According to the formulation dosage, within a temperature range of 25℃ to 60℃, thoroughly mix 5% vinyl polydimethylsiloxane (viscosity: 80000 cSt), 3% hydrogenated polydimethylsiloxane (viscosity: 100 cSt), 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% jasmine water, 2% polydimethylsiloxane PEG-10 / 15 crosspolymer, and 1% dimethyl silyl silica to form the oil phase. Take 40% deionized water and add 0.5% acrylate / C10-30 alkanol acrylate crosspolymer, dissolve and swell completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0210] Preparation of dosage form B

[0211] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinking polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinking polymer, 4.5% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 53.8% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 0.1% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0212] Application Example 4:

[0213] Preparation of dosage form A

[0214] According to the formulation dosage, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 80000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 15 cSt), 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% tulip flower extract, 4% polydimethylsiloxane PEG-10 / 15 crosspolymer, and 5% polydimethylsiloxane silylated silica to form the oil phase. Take 30% deionized water and add 0.5% acrylate / C10-30 alkanol acrylate crosspolymer, dissolve and swell completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0215] Preparation of dosage form B

[0216] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinking polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinking polymer, and 3% of silicone resin particles were mixed evenly to form the oil phase. 53.4% ​​deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 2% of the colloidal platinum composition from Example 1 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 minutes; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 minutes; an opaque gel was formed, which was then sealed and stored away from light.

[0217] Application Example 5:

[0218] Preparation of dosage form A

[0219] According to the formulation dosage, within a temperature range of 25℃ to 60℃, thoroughly mix 12% vinyl polydimethylsiloxane (viscosity: 65000 cSt), 8% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% lavender flower water, 4% polydimethylsiloxane PEG-10 / 15 crosspolymer, and 5% polydimethylsiloxane silylated silica to form the oil phase. Take 30% deionized water and add 0.5% acrylate / C10-30 alkanol acrylate crosspolymer, dissolve and swell completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0220] Preparation of dosage form B

[0221] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 10% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 47.4% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 5 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0222] Application Example 6:

[0223] Preparation of dosage form A

[0224] According to the formulation dosage, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% hydrogenated polydimethylsiloxane, 8% silica, 8% polydimethylsiloxane, 2% isononyl isononanoate, 2% sandalwood extract, and 4% polydimethylsiloxane PEG-10 / 15 crosspolymer to form the oil phase. Take 25% deionized water and add 0.5% acrylate / C10-30 alkanol acrylate crosspolymer, dissolve and swell completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0225] Preparation of dosage form B

[0226] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 1% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 56.4% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 6 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0227] Application Example 7:

[0228] Preparation of dosage form A

[0229] According to the formulation dosage, within a temperature range of 25℃ to 60℃, thoroughly mix 20% vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% hydrogenated polydimethylsiloxane, 8% silica, 8% polydimethylsiloxane, 2% isononyl isononanoate, 0.2% Rosa damascena flower oil, and 4% polydimethylsiloxane PEG-10 / 15 crosslinked polymer to form the oil phase. Take 25% deionized water and add 0.5% acrylate / C10-30 alkanol acrylate crosslinked polymer, dissolve and swell completely to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexanediol thoroughly, and continue adding the aqueous phase. Within a temperature range of 25℃ to 60℃, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, slowly cool to room temperature, forming a milky white cream, and store in a sealed container away from light.

[0230] Preparation of dosage form B

[0231] Within a temperature range of 45°C to 60°C, 15% of cyclopentamethoxysiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 1% of nylon-12, and triisostearic acid isopropoxytitanium salt were mixed evenly to form the oil phase. 56.4% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol were dissolved thoroughly to form the aqueous phase. 1% of the colloidal platinum composition from Example 6 was added separately as the additive phase. Within a temperature range of 25°C to 60°C, the aqueous phase was slowly added to the oil phase, and the mixture was stirred and homogenized for 5–15 min; then the additive phase was added, and the mixture was stirred and homogenized for another 5–15 min; an opaque gel was formed, which was then sealed and stored away from light.

[0232] Test Example 4:

[0233] Test Method: Olfactory Identification: Thirty participants were selected, all of whom had undergone prior olfactory testing. They could easily distinguish between deionized water, 1% acetic acid, and 1% β-phenylethanol. The samples were placed in a temperature- and humidity-controlled room. Participants entered the room 30 minutes before each test. Product A was first applied to the desired area of ​​the skin and, after complete absorption, Product B was applied to the same area. The duration of the fragrance was then recorded at each time point. No fragrance was 0, weak fragrance was +, medium fragrance was ++, and strong fragrance was +++.

[0234] Table 7: Fragrance Longevity Test of Perfume Balm

[0235] serial number Test sample initial 1h 2h 4h 8h 24h 1 Application Example 2 +++ +++ +++ +++ ++ + 2 Application Example 3 +++ +++ +++ +++ ++ + 3 Application Example 4 +++ +++ +++ +++ ++ + 4 Application Example 5 +++ +++ +++ +++ ++ + 5 Application Example 6 +++ +++ +++ +++ ++ + 6 Application Example 7 +++ +++ +++ +++ ++ +

[0236] As shown in Table 7, samples 1-6 of the present invention all possess excellent fragrance retention properties, achieving a fragrance retention time of 24 hours. This effectively achieves sustained fragrance release.

Claims

1. A long-lasting fragrance set comprising: (i) Dosage form A, wherein dosage form A comprises: 10-20% by weight of oil, 0.01-40% by weight of fragrance raw materials, 3-25% by weight of hydrogenated polydimethylsiloxane, with a viscosity of 10 to 130 cSt at 25°C. Vinyl polydimethylsiloxane, 5-35% by weight, with a viscosity of 55,000 to 95,000 cSt at 25°C. 1-10% by weight of emulsifier, and Acceptable carriers in the cosmetics field; and (ii) Dosage form B, wherein dosage form B comprises: 1-10% by weight of colloidal platinum composition, 1-10% by weight of light-scattering particles, Acceptable carriers in the cosmetics industry; in, The colloidal platinum composition comprises: 0.1-10% by weight of a platinum metal salt or chloroplatinic acid, wherein the platinum metal salt is selected from: potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate, or combinations thereof. 1-20% by weight of fatty acids with 8-30 carbon atoms. 0.01-5% by weight of organosilanes with 10-60 carbon atoms, A solvent acceptable in the cosmetics industry, wherein the solvent is propylene glycol.

2. The kit as described in claim 1, characterized in that, The dosage form A also contains 1-10% by weight of silica.

3. The kit as described in claim 1, characterized in that, The emulsifier in formulation A is a polydimethylsiloxane PEG-10 / 15 crosslinked polymer.

4. The kit as described in claim 2, characterized in that, The silica in dosage form A is selected from: silylated silica, dimethylsilylated silica, polydimethylsiloxane silylated silica, hydrated silica, or combinations thereof.

5. The kit as described in claim 1, characterized in that, The colloidal platinum composition in dosage form B also contains polyvinylpyrrolidone with a K value of 28-34.

6. The kit as claimed in claim 1, characterized in that, The fatty acids in the colloidal platinum composition of dosage form B are selected from: palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid, or combinations thereof.

7. The kit as claimed in claim 1, characterized in that, The organosilane in the colloidal platinum composition of dosage form B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane, or a combination thereof.

8. The kit as described in claim 1, characterized in that, The light-scattering particles in formulation B are nylon-12 and triisostearic acid isopropoxytitanium salt.

9. The kit as described in claim 1, characterized in that, The dosage form B also includes the following components: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

10. The kit as described in any one of claims 1-9, wherein the kit is in a two-dosage form or two separate packages.

11. The use of the kit as described in any one of claims 1-9 in the preparation of a cosmetic, wherein the cosmetic is used to achieve a long-lasting fragrance effect.

12. The method of using the kit for non-therapeutic purposes as described in any one of claims 1-9, comprising applying dosage form A evenly to the skin surface until absorbed, and then applying dosage form B to the skin surface.

Images